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Obesity, Waist Circumference, Weight
Change, and Risk of Incident Psoriasis:
Prospective Data from the HUNT Study
Ingrid Snekvik1,2, Catherine H. Smith3, Tom I.L. Nilsen1, Sine´ad M. Langan4, Ellen H. Modalsli1,2,
Pa˚l R. Romundstad1 and Marit Saunes2,5
Although psoriasis has been associated with obesity, there are few prospective studies with objective mea-
sures. We prospectively examined the effect of body mass index, waist circumference, waist-hip ratio, and
10-year weight change on the risk of developing psoriasis among 33,734 people in the population-based Nord-
Trøndelag Health Study (i.e., HUNT), Norway. During follow-up, 369 incident psoriasis cases occurred. Relative
risk (RR) of psoriasis was estimated by Cox regression. One standard deviation higher body mass index, waist
circumference, and waist-hip ratio gave RRs of 1.22 (95% confidence interval [CI] ¼ 1.11e1.34), 1.26 (95% CI ¼
1.15e1.39), and 1.18 (95% CI ¼ 1.07e1.31), respectively. Compared with normal weight participants, obese
people had an RR of 1.87 (95% CI ¼ 1.38e2.52), whereas comparing the fourth with the first quartile of waist
circumference gave an RR of 1.95 (95% CI ¼ 1.46e2.61). One standard deviation higher weight change gave an
RR of 1.20 (95% CI ¼ 1.07e1.35), and people who increased their body weight by 10 kg or more had an RR of 1.72
(95% CI ¼ 1.15e2.58) compared with being weight stable. In conclusion, obesity and high abdominal fat mass
doubles the risk of psoriasis, and long-term weight gain substantially increases psoriasis risk. Preventing weight
gain and promoting maintenance of a normal body weight could reduce incidence of psoriasis.
Journal of Investigative Dermatology (2017) 137, 2484e2490; doi:10.1016/j.jid.2017.07.822
INTRODUCTION
Psoriasis is a chronic inflammatory skin disease with an
estimated prevalence of 2e4% in most European countries
(Parisi et al., 2013) and 6e11% in Norway (Danielsen et al.,
2013; Modalsli et al., 2016). Psoriasis may have major impact
on everyday life, and there is evidence that individuals with
psoriasis may die at younger ages (Abuabara et al., 2010;
Gelfand et al., 2007; Stern et al., 2004). The Global Burden
of Disease Study (Murray et al., 2015) reported that psoriasis
made up a substantial part (0.19%) of the total global
disability-adjusted life-years, and yearly costs due to treat-
ment and loss of work are high (Feldman et al., 2014;
Svedbom et al., 2016).
Obesity is a growing public health challenge, both globally
(World Health Organization, 2000) and in Norway (Meyer
and Tverdal, 2005; Midthjell et al., 2013). Recent studies
also support increasing psoriasis prevalence and incidence
(Danielsen et al., 2013; Icen et al., 2009). A large number of
observational studies have shown that people with psoriasis
are more likely to be obese (Armstrong et al., 2012), but the
temporal relationship is still unclear. Obesity may be a
common underlying factor explaining the positive associa-
tions between psoriasis and comorbidities such as cardio-
vascular disease (Samarasekera et al., 2013), diabetes
(Armstrong et al., 2013), and metabolic syndrome (Prey et al.,
2010), or alternatively, obesity could be causally related to
psoriasis onset. Two prospective studies from the United
States reported a positive association between measures of
adiposity, such as body mass index (BMI), waist circumfer-
ence, and waist-hip ratio, and the risk of incident psoriasis in
women (Kumar et al., 2013; Setty et al., 2007). Findings from
a recent Norwegian study suggest that there might be a
threshold around a BMI of 28 kg/m2, above which psoriasis
risk is increased (Danielsen et al., 2017). Moreover, self-
reported weight gain since early adulthood has also been
positively related to psoriasis risk (Danielsen et al., 2017;
Kumar et al., 2013; Setty et al., 2007). Taken together, these
previous longitudinal studies indicate that obesity and weight
gain may increase psoriasis risk. However, because of sparse
data on men, reliance on self-reported weight and other
anthropometric measures that may be prone to bias, and
heterogeneous and imprecise associations, the evidence is
not conclusive.
If obesity is associated with an increased risk of psoriasis, it
is important to know whether there is a specific, incremental
weight gain required to trigger incident disease. Such
knowledge could have important implications for public
health and may provide a means to prevent psoriasis onset in
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individuals with genetic predisposition (World Health
Organization, 2016). In a large, longitudinal study with
objective measures of various indicators of adiposity, we
prospectively examined if overweight and obesity defined by
BMI were associated with the subsequent risk of incident
psoriasis. We also examined if other measures of adiposity
and body fat distribution, including waist circumference and
waist-hip ratio, were associated with psoriasis risk. Finally,
we assessed if long-term changes in body weight and BMI
were associated with subsequent psoriasis risk and if this
association depended on the initial body mass.
RESULTS
A total of 33,734 individuals were included: 18,499 (55%)
women and 15,235 (45%) men. Of these, 369 individuals
developed psoriasis during the follow-up period: 185 women
and 184 men. The mean age was 47.0 years, with a standard
deviation (SD) of 13.3. Baseline characteristics of the study
population stratified by BMI categories are shown in more
detail in Table 1. We found no evidence of violation of the
proportional hazards assumption for any of the analyses
presented below.
Table 2 shows that the risk of incident psoriasis was posi-
tively associated with all body composition measures. A one-
SD (3.81 kg/m2) increase in BMI was associated with an
adjusted relative risk (RR) of 1.22 (95% confidence interval
[CI] ¼ 1.11e1.34). The adjusted associations for one-SD
increase in waist circumference (11.14 cm) and waist-hip
ratio (0.08) were of largely the same magnitude, with RRs
of 1.26 (95% CI ¼ 1.15e1.39) and 1.18 (95% CI ¼
1.07e1.31). Analyses of categorized factors showed that
obese people had nearly twice the risk of psoriasis (RR ¼
1.87; 95% CI ¼ 1.38e2.52) compared with normal weight
people. Comparing extreme categories (fourth and first
quartiles) of waist circumference gave an RR of the same
magnitude as for BMI, whereas for waist-hip ratio the asso-
ciation was somewhat weaker. Additional adjustment for
physical activity and alcohol consumption did not change the
results. Sensitivity analyses excluding individuals with onset of
psoriasis within the first year after the second Nord-Trøndelag
Health Study (HUNT2) did not substantially change the results
described (data not shown). Although there was no evidence
of statistical interaction by sex (all P-values > 0.09), stratified
analyses gave associations that were somewhat stronger for
men than for women (see Supplementary Table S1 online).
Attributable fractions calculated from the estimated associa-
tions suggest that 23.6% of psoriasis cases in the study
population can be attributed to either overweight (population
attributable fraction ¼ 14.9%) or obesity (population attrib-
utable fraction ¼ 8.7%).
For the subset of participants with information regarding
10-year weight change from the HUNT1 to HUNT2 studies,
we found an RR of 1.20 (95% CI ¼ 1.07e1.35) for every SD
(5.96 kg) increase in weight change (Table 2). Compared with
those with nearly unchanged weight (e2.0 to 1.9 kg), people
who increased their weight by 5.0e9.9 kg had an RR of 1.33
(95% CI ¼ 0.90e1.95), whereas those who increased by 10.0
kg or more had an RR of 1.72 (95% CI ¼ 1.15e2.58). We
repeated the analyses of weight change stratifying on the
initial BMI category (data not tabulated). Persons who were
classified as normal weight at HUNT1 had RRs of 2.19 (95%
CI ¼ 1.22e3.94) and 2.83 (95% CI ¼ 1.54e5.22) associated
with a weight gain of 5.0e9.9 kg and 10.0 kg or greater,
respectively. Conversely, among initially overweight/obese
people, a weight reduction of 2.0 kg or more was associated
with an RR of 0.52 (95% CI ¼ 0.22e1.21).
Table 3 shows the risk for psoriasis in joint categories of BMI
from HUNT1 and HUNT2. Compared with those who were
normal weight at both surveys, persons who were stably over-
weight had an RR of 1.53 (95%CI¼ 1.07e2.19), and those who
were obese at both surveys had an RR of 2.16 (95% CI ¼
1.29e3.62), whereas changing from normal weight to over-
weightwas associatedwith anRRof 1.57 (95%CI¼ 1.14e2.17).
DISCUSSION
Statement of principal findings
In this large prospective study with up to 13 years of follow-
up, we found that overweight and obesity were positively
associated with risk of psoriasis. People classified as obese at
baseline had a nearly 2-fold higher risk of psoriasis compared
with those who were normal weight. Additional measures of
adiposity and fat distribution, such as waist circumference
and waist-hip ratio, were also positively associated with risk
of psoriasis. Moreover, a weight gain of 10 kg or more during
the preceding 10 years was associated with a substantially
increased risk of psoriasis compared with being weight sta-
ble, particularly among those who were initially normal
weight. There was suggestive evidence that a weight decrease
was associated with reduced risk of psoriasis, but low sta-
tistical precision calls for cautious interpretation of these re-
sults. From a public health perspective, nearly a quarter of
psoriasis cases could be attributed to overweight or obesity if
the estimated associations reflect causal relations.
Table 1. Characteristics according to categories of
body mass index (BMI) at baseline (HUNT2)
Characteristics
BMI, kg/m2
18.5e24.9
(n [ 13,904)
25e29.9
(n [ 15,010)
‡30
(n [ 4,820)
Sex
Women, n (%) 8,675 (62.4) 6,968 (46.4) 2,856 (59.3)
Men, n (%) 5,229 (37.6) 8,042 (53.6) 1,964 (40.8)
Age, mean (SD), years 43.6 (13.0) 48.5 (12.9) 50.0 (13.1)
BMI, mean (SD), kg/m2 22.8 (1.5) 27.1 (1.4) 32.9 (2.9)
Waist circumference,
mean (SD), cm
77.3 (7.9) 88.2 (7.7) 99.6 (9.2)
Hip circumference,
mean (SD), cm
96.2 (4.9) 103.4 (4.6) 113.0 (7.2)
Waist-hip ratio,
mean (SD)
0.80 (0.07) 0.85 (0.07) 0.88 (0.08)
Smoking status
Never, n (%) 6,463 (46.5) 6,782 (45.2) 2,257 (46.8)
Former, n (%) 3,146 (22.6) 4,746 (31.6) 1,604 (33.2)
Current, n (%) 4,295 (30.9) 3,482 (23.2) 959 (19.9)
Education
<10 years, n (%) 3,461 (24.9) 4,931 (32.9) 2,048 (42.5)
10e12 years, n (%) 6,748 (48.5) 6,877 (45.8) 2,057 (42.7)
13 years, n (%) 3,695 (26.6) 3,202 (21.3) 715 (14.8)
Abbreviations: HUNT, Nord-Trøndelag Health Study; SD, standard
deviation.
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Comparison with other studies
Most previous studies on the association between obesity
and psoriasis have been cross-sectional studies or retro-
spective case-control studies (Armstrong et al., 2012; Gui
et al., 2017; Kwa and Silverberg, 2017). Thus, the direc-
tion of the association has been difficult to disentangle. We
prospectively examined the association between obesity
and psoriasis in a sample of people without psoriasis who
were followed up for incident psoriasis for approximately
10 years; this gave us the opportunity to determine the di-
rection of the association between obesity and psoriasis.
Our findings of almost doubled risk of incident psoriasis in
obese participants compared with normal weight partici-
pants are in agreement with two former studies (Kumar
et al., 2013; Setty et al., 2007). A previous study from
Norway found inconsistent evidence for a relationship be-
tween BMI and risk of psoriasis; a conventional classifica-
tion of BMI gave weak and imprecise associations, whereas
the results suggested that there might be a threshold around
28 kg/m2 at which the risk of psoriasis increases (Danielsen
et al., 2017). A recent cohort study from Korea showed
weak positive associations between obesity and incident
psoriasis (Kim et al., 2017), and a nested case-control study
from the United Kingdom General Practice Research
Database (Huerta et al., 2007) found a 30% increased risk
of developing psoriasis in obese individuals. However, it
could be speculated that a sample obtained from a general
practitioner database differs from the general population
when it comes to health status and morbidity, and that such
selection could have influenced the estimated association
between obesity and psoriasis.
BMI is a commonly used measure of body composition,
but evidence suggests that measures reflecting abdominal
adiposity, such as waist circumference and waist-hip ratio,
are better indicators of metabolic abnormalities and car-
diovascular disease risk (World Health Organization, 2011).
There are two previous studies restricted to women that
have investigated waist circumference and waist-hip ratio
with regard to risk of psoriasis (Kumar et al., 2013; Setty
et al., 2007). These studies found the risk to be highest in
the uppermost categories and are in accordance with the
results of this population-based study.
Table 2. Relative risk of incident psoriasis associated with body mass index, waist circumference, waist-hip ratio,
and weight change
Variables
Number of
Person-Years
Incident
Psoriasis Cases Rate1 Crude RR (95% CI) Adjusted RR2 (95% CI)
Body mass index, kg/m2
18.5e24.9 154,838 122 7.9 1.00 (Reference) 1.00 (Reference)
25.0e29.9 166,586 178 10.7 1.36 (1.08e1.71) 1.45 (1.15e1.84)
30.0 53,327 69 12.9 1.64 (1.22e2.20) 1.87 (1.38e2.52)
Body mass index, per SD (3.81 kg/m2) 374,750 369 9.8 1.17 (1.07e1.29) 1.22 (1.11e1.34)
Body mass index, per kg/m2 374,750 369 9.8 1.04 (1.01e1.07) 1.05 (1.03e1.08)
Waist circumference (quartiles)3
First 108,860 82 7.5 1.00 (Reference) 1.00 (Reference)
Second 84,565 80 9.5 1.25 (0.92e1.71) 1.33 (0.98,e1.81)
Third 87,086 88 10.1 1.34 (0.99e1.81) 1.48 (1.09e2.00)
Fourth 91,477 117 12.8 1.68 (1.26e2.23) 1.95 (1.46e2.61)
Waist circumference, per SD (11.14 cm) 383,953 367 9.9 1.21 (1.10e1.33) 1.26 (1.15e1.39)
Waist circumference, per cm 383,953 367 9.9 1.02 (1.01e1.03) 1.02 (1.01e1.03)
Waist-hip ratio (quartiles)4
First 94,793 80 8.4 1.00 (Reference) 1.00 (Reference)
Second 92,330 91 9.9 1.17 (0.87e1.58) 1.19 (0.88e1.61)
Third 93,151 85 9.1 1.08 (0.80e1.47) 1.13 (0.83e1.54)
Fourth 91,713 111 12.1 1.43 (1.07e1.91) 1.53 (1.14e2.07)
Waist-hip ratio, per SD (0.08) 371,987 367 9.9 1.15 (1.05e1.27) 1.18 (1.07e1.31)
Waist-hip ratio, per 0.1 unit 371,987 367 9.9 1.25 (1.10e1.43) 1.35 (1.12e1.61)
Weight change from HUNT1 to HUNT2, kg
<e2.0 18,864 10 5.3 0.68 (0.34e1.38) 0.66 (0.32e1.33)
e2.0 to 1.9 47,843 37 7.7 1.00 (Reference) 1.00 (Reference)
2.0e4.9 62,939 51 8.1 1.05 (0.69e1.60) 1.05 (0.69e1.61)
5.0e9.9 91,232 92 10.0 1.31 (0.89e1.91) 1.33 (0.90e1.95)
10.0 58,295 77 13.2 1.71 (1.15e2.52) 1.72 (1.15e2.58)
Weight change, per SD (5.96 kg) 279,172 267 9.6 1.21 (1.08e1.36) 1.20 (1.07e1.35)
Weight change, per kg 279,172 267 9.6 1.03 (1.01e1.05) 1.03 (1.01e1.05)
Abbreviations: CI, Confidence interval; HUNT, Nord-Trøndelag Health Study; RR, relative risk, SD, standard deviation.
1Incidence of psoriasis per 10,000 person-years.
2Adjusted for age (continuous), sex, education (<10 years, 10e12 years, 13 years) and smoking (never, former, current).
3Waist circumference quartiles for men: first, 86 cm; second, 87e90 cm; third, 91e96 cm; fourth, 97 cm; for women: first, 73 cm; second, 74e79 cm;
third, 80e86 cm; fourth, 87 cm.
4Waist hip ratio quartiles for men: first, 0.86; second, 0.86e0.89; third, 0.89e0.92; fourth, 0.92; for women: first, 0.75; second, 0.75e0.79; third,
0.79e0.82; fourth,  0.82.
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We also studied weight change before baseline. Former
studies have found weight gain to be a risk factor for onset of
psoriasis (Danielsen et al., 2017; Kumar et al., 2013; Setty
et al., 2007), which is consistent with our findings. Howev-
er, whereas we used objectively measured weight 10 years
before baseline, those studies relied on self-reported weight
at ages 18 and 25 years. Despite low statistical power, our
results also indicate that weight loss may be beneficial with
regard to the risk of developing psoriasis.
Potential biological mechanisms
Our findings that adiposity is associated with psoriasis risk,
with the strongest association for central obesity, suggest that
fat mass plays a role in disease causation (Versini et al.,
2014). This is in contrast to the more often cited mecha-
nism where “systemic inflammation” associated with psori-
asis leads to weight gain and fat redistribution. Adipose
tissue, especially visceral fat, produces adipokines, which
have a role in chronic inflammation. Adipokines that display
pro-inflammatory activities such as leptin, visfatin, and
resistin are increased in psoriasis patients, whereas the level
of adiponectin, an anti-inflammatory adipokine, is decreased
(Toussirot et al., 2014). Resident macrophages within adipose
tissue contribute in the production of psoriasis-signature cy-
tokines such as IL-6 and tumor necrosis factor-a, which are
also thought to induce insulin resistance and may lead to
altered lipid metabolism, hypertension, and enhanced risk of
cardiovascular disease (Chiricozzi et al., 2016). Inflammation
has also been proposed as a possible mechanism for other
obesity-associated diseases, such as asthma (Ali and Ulrik,
2013) and rheumatoid arthritis (Feng et al., 2016). Other
mechanisms could involve a common genetic link between
psoriasis and obesity, as suggested in a recent twin study
(Lonnberg et al., 2016).
Strengths and limitations
The strengths of this study include the population-based
sample, prospective design, and large number of participants
with information on objectively measured body height,
weight, and waist circumference, as well as 10-year weight
change. Standardized measurement methods limit possible
misclassification bias. The number of new psoriasis cases
provided relatively high precision in the estimated associa-
tions, particularly for the continuous body mass measures.
However, for some of the less prevalent exposure categories,
especially regarding weight change, the estimates were more
imprecise. To our knowledge, this is the largest population-
based study to date that includes several obesity-related
measurements from both men and women. Two studies from
the United States have included women only (Kumar et al.,
2013; Setty et al., 2007) and thus where not able to
examine possible sex differences in the association between
adiposity and psoriasis. Whereas a former Norwegian study
suggested a slightly stronger effect of BMI for women than
men (Danielsen et al., 2017), our estimates suggest somewhat
stronger associations in men than in women for all body mass
measures. However, the results from these stratified analyses
have lower precision than the overall findings and are thus
more influenced by chance. A recent validation study from our
research group showed that the self-report of psoriasis in the
HUNT3 study had a positive predictive value of 78% and a
negative predictive value of 96%, with a sensitivity of 56%
and a specificity of 99% (Modalsli et al., 2016). Although
several cases remain undetected in the study cohort, these
figures also imply that four out of five people classified as
having psoriasis in our study are true cases. However, to
identify new cases of psoriasis occurring after baseline we had
to rely on self-reported year of diagnosis. Few studies have
validated self-reported age at onset of disease, but studies on
asthma have found a high reliability of the reported age at
onset (Mirabelli et al., 2014; Pattaro et al., 2007; Toren et al.,
2006). However, it is conceivable that some of the psoriasis
cases with reported onset just after baseline were not true
incident cases, but sensitivity analysis excluding the first year
of follow up did not change the results.
The inhabitants in the county of Nord-Trøndelag are
considered representative of the Norwegian population
(Langhammer et al., 2012). Studies have indicated that non-
participants are older, have higher morbidity and mortality,
and have lower socioeconomic status than participants
(Langhammer et al., 2012). However, representativeness is
not necessarily a prerequisite for validity (Rothman et al.,
2013). Still, there is potential for selection bias because
participants must have attended both HUNT2 and HUNT3 to
be included in this study. It is conceivable that individuals
with high BMI had increased morbidity and mortality be-
tween the surveys and were therefore less likely to participate
at follow up, which may have underestimated the observed
associations between obesity and psoriasis. Moreover, it is
unclear whether obese people have a different health seeking
behavior than normal weight people that could influence the
likelihood of being diagnosed with psoriasis. We were able to
adjust for several factors that could act as confounders, but
residual confounding because of unmeasured or poorly
measured factors cannot be ruled out. For instance, we did
not have information on nutrition or genetic variants that
could be common to obesity and psoriasis. Moreover, we
used complete case strategy, whereby people with missing
Table 3. Multivariable1 relative risk of psoriasis
according to weight categories in HUNT1 and HUNT2
BMI Category
at HUNT1
BMI Category at HUNT2
18.5e24.9
kg/m2
25.0e29.9
kg/m2
‡30.0
kg/m2
18.5e24.9 kg/m2
Cases/person-years 72/98,301 77/70,540 3/3,142
RR (95% CI) 1.00 1.57
(1.14e2.17)
1.31
(0.41e4.18)
25.0e29.9 kg/m2
Cases/person-years 6/3,925 59/59,457 27/25,135
RR (95% CI) 2.15
(0.93e4.96)
1.53
(1.07e2.19)
1.69
(1.08e2.65)
30.0 kg/m2
Cases/person-years 0/67 0/1,196 19/14,860
RR (95% CI) NC NC 2.16
(1.29e3.62)
Abbreviations: BMI, body mass index; CI, confidence interval; HUNT,
Nord-Trøndelag Health Study; NC, not calculated; RR, relative risk.
1Adjusted for age (continuous), sex, education (<10 years, 10e12 years,
13 years) and smoking (never, former, current).
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information on possible confounders were excluded. This
may reduce the possibility for residual confounding because
of misclassification, but although few people were excluded,
this could potentially increase selection bias.
CONCLUSIONS AND IMPLICATIONS
In conclusion, our study supports former findings that body
weight is associated with psoriasis risk, and we found a
consistent dose-response relationship across multiple
obesity-related measurements. Strong associations between
waist circumference and psoriasis risk could indicate that
central adiposity plays an important role in disease devel-
opment. We also found that the risk of psoriasis was sub-
stantially increased among people with a long-term weight
gain of 10 kg or more, whereas there was suggestive evidence
that weight loss could reduce psoriasis risk. These data
indicate that obesity is an important, potentially modifiable
risk factor in the development of psoriasis that provides an
opportunity for disease prevention.
METHODS
Data source
The HUNT Study is a large population-based longitudinal study
conducted within the county of Nord-Trøndelag, Norway. All resi-
dents in the county age 20 years or older have been invited to
participate in the study at three different surveys. At HUNT1
(1984e1986), 86,404 persons were invited, and 77,212 (89%) chose
to participate; at HUNT2 (1995e1997) 93,898 were invited, and
65,237 (70%) participated; and at HUNT3 (2006e2008) 93,860
were invited and 50,807 (54%) participated (Krokstad et al., 2013).
Comprehensive questionnaires were completed to obtain informa-
tion on health and lifestyle related factors, including psoriasis
(HUNT3), smoking history, and educational attainment. Standard-
ized measures of height, weight, waist circumference, and hip
circumference were obtained at clinical examinations of all partic-
ipants. More detailed information about participation, examinations,
and questionnaires can be found at http://www.ntnu.edu/hunt.
Study population
For the purpose of this prospective study of adiposity and risk of
psoriasis, we selected all 36,968 persons who had participated in
both the HUNT2 and HUNT3 surveys (Figure 1). Of these, 3,234
persons were excluded because of either missing information on
psoriasis at HUNT3; having a psoriasis diagnosis at baseline in
HUNT2; or missing information on height, weight, education, and
smoking at HUNT2. People with a BMI of less than 18.5 kg/m2 at
HUNT2 were also excluded because of few cases in this group. After
these exclusions, a total of 33,734 persons who were free from
psoriasis at HUNT2 were available for statistical analyses of BMI and
risk of psoriasis. Because of missing data on waist circumference
(n ¼ 249) and waist-hip ratio (n ¼ 249), the analyses of these factors
were conducted on a slightly smaller sample. Additionally, we used
information on objectively measured body weight on 25,148 per-
sons who participated in all three HUNT surveys to examine if
weight change from HUNT1 (1984e1986) to HUNT2 (1995e1997)
was related to subsequent risk of psoriasis.
HUNT2
(n = 65,237)
HUNT3
(n = 50,805)
Participated in both HUNT2 and 
HUNT3
(n = 36,968)
Exclusions (n = 3,234)
•Missing data on psoriasis at HUNT3 (n = 5)
•Missing data on age at onset of psoriasis 
(n = 676)
•Psoriasis diagnosis before HUNT2
(n = 1,168)
•Missing data on BMI at HUNT2 (n = 123)
•Missing data on education (n = 802)
•Missing data on smoking (n = 272) 
•BMI <18.5 kg/m2 at HUNT2 (n = 188)
Available for statistical analyses
(n = 33,734)
Figure 1. Flow chart. Selection and
exclusion procedures of participants
for statistical analyses. BMI, body
mass index; HUNT, Nord-Trøndelag
Health Study.
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Outcome: Psoriasis diagnosis
Information on psoriasis was obtained at follow-up in HUNT3 using
the question, “Do you have or have you had any of the following?”
and where “Psoriasis (Yes, No)” was one of the response options.
Participants with a positive response to the question were asked
about the age at onset of psoriasis. We used this information to
calculate follow-up time from participation in HUNT2 until onset of
psoriasis between HUNT2 and HUNT3. 1,168 people with a pso-
riasis diagnosis before HUNT2 were excluded, and the follow-up
time for people without psoriasis was calculated as the difference
in age between participation in HUNT2 and HUNT3.
Exposures: Body mass measurements
Main exposures were BMI, waist circumference, and waist-hip
ratio. All exposures were assessed using standardized method-
ology. Specifically, at the clinical examination, specially trained
nurses or technicians recorded body height and body weight with
the participants wearing light clothes and no shoes. Height was
measured to the nearest centimeter and weight to the nearest half
kilogram. BMI was calculated as weight divided by the squared
value of height (kg/m2) and classified into three categories;
normal weight (18.5e24.9 kg/m2), overweight (25.0e29.9 kg/
m2), and obese (30.0 kg/m2) (World Health Organization,
2000). Waist and hip circumference were measured with a steel
band to the nearest centimeter; waist circumference was
measured at the level of the umbilicus and hip circumference at
the thickest part of the hip (Holmen et al., 2003). Waist-hip ratio
was calculated as waist circumference (cm) divided by hip
circumference (cm). Based on the distribution of waist circum-
ference and waist-hip ratio, we classified people into four cate-
gories using the sex-specific quartiles as cut-offs: for waist
circumference the cut-offs were 86, 90, and 96 cm in men and
73, 79, and 87 cm in women; for waist-hip ratio the cut-offs were
0.86, 0.89, and 0.92 in men and 0.75, 0.79, and 0.82 in women.
In the subsample of persons with information on body weight
from HUNT1 we calculated the 10-year change in body weight
from HUNT1 to HUNT2 by subtracting weight at HUNT1 from
weight at HUNT2 and categorized people into five arbitrary
groups: less than e2.0 kg, e2.0 to 1.9 kg, 2.0 to 4.9 kg, 5.0 to 9.9
kg, and 10.0 kg or greater. Finally, we calculated sex-specific SD
scores (z-scores) for all the anthropometric measures as the
observed value minus the sex-specific mean value, divided by the
sex-specific SD.
Analysis
We used Cox regression to calculate hazard ratios as estimates of RR
for incident psoriasis within categories of BMI, waist circumference,
and waist-hip ratio measured at HUNT2, and weight change be-
tween HUNT1 and HUNT2, compared with a reference category.
We also estimated RRs associated with continuous measures of the
anthropometric variables, using both the original scale and sex-
specific normalized values (z-scores). The precision of all estimates
was assessed by 95% CI. We selected potential confounders based
on a priori considerations of factors that are related to both psoriasis
risk and body mass measures. All estimated associations were
adjusted for possible confounding by age (years), sex (women, men),
smoking (never smoker, former smoker, and current smoker), and
education (<10 years [i.e., elementary school], 10e12 years [i.e.,
high school], and 13 years [i.e., college/university]). Other factors,
such as physical activity and alcohol consumption, could also be
possible confounders, although the rationale is less clear. In
additional analyses, we also adjusted for physical activity (no, low,
medium, high, and unknown [n ¼ 1,621]) and alcohol consumption
(no, 1e4 times per week, 5 times per week, abstainer, and un-
known [n ¼ 2,306]).
Assuming that the estimated associations reflect causal relations
between high BMI and psoriasis, we calculated the population
attributable fraction (Rothman, 2012) to quantify the proportion of
psoriasis that could be attributed to overweight and obesity. Because
adipose tissue could be differentially distributed and have differen-
tial biological effects between men and women, we conducted an-
alyses stratified by sex and evaluated possible statistical interaction
(i.e., departure from multiplicative effect) in a likelihood ratio test of
a product term of sex and the relevant anthropometric factor. To
reduce the influence of imprecise reporting of age at onset of pso-
riasis and possible reverse causality because of existing undiagnosed
disease, we also conducted sensitivity analyses excluding people
who reported onset of psoriasis during the first year after HUNT2
(n ¼ 38).
Departure from the proportional hazards assumption was evalu-
ated by tests of Schoenfeld residuals and by graphical inspection of
log-log plots. All analyses were conducted using Stata for Windows
(Version IC 14.1, StataCorp, College Station, TX).
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